Inventor · disambiguated record
Shantanu Sule
Also filed as: SULE SHANTANU · SULE SHANTANU VIRENDRA
2 granted patents·8 pending applications·1 citations·filing 2016–2025
35Inventor score
Top patents by PatentIndex Score
10 records- 0170US11655289B2Pharmaceutical compositions containing anti-beta amyloid antibodiesBIOGEN MA INC·Filed 2018·Granted May 23, 2023·1 cites·18 claims
- 0260US2024043513A1Pharmaceutical compositions containing anti-beta amyloid antibodiesBIOGEN MA INC·Filed 2023·Application pending·0 cites
- 0358US11510967B2Pharmaceutical combinations comprising insulin and at least an agent selected from meloxicam, bromfenac sodium, acetylsalicylic acid, salicyclic acid and paracetamolLILLY CO ELI·Filed 2018·Granted Nov 29, 2022·0 cites·11 claims
- 0458US2025215086A1Anti-pd-1 antibody formulationsAMGEN INC·Filed 2023·Application pending·0 cites
- 0556US2025289895A1Pharmaceutical compositions and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 antibodiesBIOGEN MA INC·Filed 2025·Application pending·0 cites
- 0654US2022175891A1Pharmaceutical combinations comprising insulin and at least an agent selected from meloxicam, bromfenac sodium, acetylsalicylic acid, salicyclic acid and paracetamolLILLY CO ELI·Filed 2021·Application pending·0 cites
- 0740US2019284281A1Pharmaceutical compositions and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 antibodiesBIOGEN MA INC·Filed 2017·Application pending·0 cites
- 0840US2022144945A1Pharmaceutical compositions containing anti-lingo-1 antibodiesBIOGEN MA INC·Filed 2020·Application pending·0 cites
- 0934US2018264112A1Anti-CD40 Antibody FormulationsBIOGEN MA INC·Filed 2016·Application pending·0 cites
- 1032US2019064147A1Formulations and screening of biological therapeutic agentsBIOGEN MA INC·Filed 2016·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →